Our work thus illuminates a profound dysregulation of this cell cycle-regulated network and facilitates a deeper understanding of the tumor biology of AR-low TNBC and potentially QNBC while also pointing to possible treatment targets that might specifically benefit this high-need patient subgroup. Here, AR is linked to neoplasm.